NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Intellia Therapeutics Inc (NTLA) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite some positive catalysts like the FDA lifting the clinical hold and progress in clinical trials, the company's financial performance is weak, insider selling is significant, and technical indicators suggest a mixed outlook. The lack of strong trading signals and limited upside potential in the short term further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 75.017, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is currently trading near resistance levels (R1: 13.961, R2: 14.69), suggesting limited immediate upside. Pre-market price is $14.13, down 1.05%, reflecting bearish sentiment.
The FDA's new draft guidance for rare diseases could expedite approval processes, benefiting NTLA.
Insider selling has surged by 2235.78% in the last month, signaling potential lack of confidence from internal stakeholders. Financial performance is weak, with declining net income, EPS, and gross margin. The stock has a 70% chance of declining by 3.34% in the next day.
In Q4 2025, revenue increased by 78.79% YoY to $23.02 million, but net income dropped by 25.69% YoY to -$95.79 million. EPS fell by 34.65% YoY to -$0.83, and gross margin dropped to 0%. Cash reserves declined to $605.1 million.
Analysts are mixed. H.C. Wainwright raised the price target to $25 with a Buy rating, citing manageable clinical risks. Citizens reiterated an Outperform rating with a $21 price target, highlighting valuation disconnects. Baird and BofA maintain Neutral ratings with price targets of $7 and $12, respectively, citing cautious sentiment and broader biotech concerns.
